Literature DB >> 2513107

Biochemistry of the lipoxygenase pathways in neutrophils.

P Borgeat1.   

Abstract

Three mammalian lipoxygenases have been reported to date. They catalyze the insertion of oxygen at positions 5, 12, and 15 of various 20-carbon polyunsaturated fatty acids. In the case of arachidonic acid, the immediate products are hydroperoxyeicosatetraenoic acids (HPETEs). HPETEs can undergo different transformations. One reaction is a reduction of the hydroperoxy group yielding the corresponding hydroxyeicosatetraenoic acids (HETEs). In the neutrophils, the major pathway of arachidonic acid metabolism is the 5-lipoxygenase. In these cells the 5-HPETE undergoes a cyclization reaction leading to a 5(6)-epoxy(oxido)eicosatetraenoic acid or leukotriene A4. The 5(6)-epoxy fatty acid can undergo three additional transformations: (a) a nonenzymatic hydrolysis to epimeric dihydroxyeicosatetraenoic acids (diHETEs); (b) stereospecific enzymatic hydrolysis to a specific diHETE, leukotriene B4; or (c) ring opening by reduced glutathione (GSH) to yield a peptidolipid, named leukotriene C4, in which GSH is attached via a sulfoether linkage. The leukotrienes constitute a group of biologically active substances probably involved in allergic and inflammatory reactions. The 5(6)-epoxy-eicosatetraenoic acid and the products derived from it contain a conjugated triene unit; the term leukotriene also denotes the cells (leukocytes) recognized to form these products, mainly the neutrophils, eosinophils, basophils, monocytes, mast cells, and macrophages. In the present article various aspects of the biochemistry of the lipoxygenase pathways of neutrophils are reviewed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513107     DOI: 10.1139/y89-147

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  8 in total

1.  Lipoxins and other arachidonate derived mediators in bronchial asthma.

Authors:  C Chavis; I Vachier; P Godard; J Bousquet; P Chanez
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes.

Authors:  Michelle M Armstrong; Giovanni Diaz; Victor Kenyon; Theodore R Holman
Journal:  Bioorg Med Chem       Date:  2014-05-21       Impact factor: 3.641

3.  Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction.

Authors:  D Riendeau; J P Falgueyret; J Guay; N Ueda; S Yamamoto
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

4.  Thrombin-activated platelets promote leukotriene B4 synthesis in polymorphonuclear leucocytes stimulated by physiological agonists.

Authors:  R Palmantier; P Borgeat
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

5.  Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats.

Authors:  Caroline Bélanger; Hanan Elimam; Julie Lefebvre; Pierre Borgeat; Sylvie Marleau
Journal:  Immunology       Date:  2008-01-24       Impact factor: 7.397

6.  5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors.

Authors:  C Chavis; I Vachier; P Chanez; J Bousquet; P Godard
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

7.  Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways.

Authors:  Jeffrey A Ericson; Pierre Duffau; Kei Yasuda; Adriana Ortiz-Lopez; Katherine Rothamel; Ian R Rifkin; Paul A Monach
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

8.  Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils.

Authors:  M Pouliot; P P McDonald; P Borgeat; S R McColl
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.